Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects currently enrolled in study 20050103, 20050136, or 20050244
Subjects must sign the informed consent before any study specific procedures are performed
You may not be if
Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study
Currently receiving any unapproved investigational product other than denosumab
Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
Subject (male or female) is not willing to use 2 highly effective contraception during treatment and for 7 months (women) or 10 months (men) after the end of treatment
Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment
Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
Clareo Health | Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
